glp 1 chronic pain Full article: GLP-1 agonists: a game changer in treatment and addiction Indigestion from GLP-1 Injections -

Phase two trials of the US biotech companys obesity pill showed weight loss of 12.2 percent but a higher rate of patient drop-off compared to a placebo.

However, that is not the reality: even diabetic patients treated with GLP-1 RAs are more likely to stop them than other second-line anti-diabetic medicines.3 That study didnt report why 50% of diabetics on GLP-1 RAs discontinued them, but gastrointestinal (GI) adverse events were a suggested cause.3 Adverse events are just one of a number of reasons that people stop using these drugs, as follows.

GLP-1s, here to stay

Truveta Research explores patterns of GLP-1 RA switching from 2018 to 2023 and demographic characteristics of patients who switched.

Genetically-predicted GLP1R expression (the target of GLP-1 RAs) showed an inverse association with background [odds ratio (OR)=0.83, 95% CI, 0.710.97] and severe nonproliferative DR (OR=0.72, 95% CI, 0.530.98), and a non-significant association with overall (OR=0.97, 95% CI, 0.921.03) and proliferative DR (OR=0.98, 95% CI, 0.911.05)